BACKGROUND: @entity1 with @entity4905 ( @entity4905 ) or @entity64 are at high immediate risk of @entity64 . The optimum early treatment options for these @entity1 are not known. METHODS: Within 24 h of symptom onset, we randomly assigned, in a factorial design, 392 @entity1 with @entity4905 or @entity64 to @entity1397 (300 mg loading dose then 75 mg daily; 198 @entity1 ) or placebo (194 @entity1 ), and @entity3413 (40 mg daily; 199 @entity1 ) or placebo (193 @entity1 ). All @entity1 were also given @entity117 and were followed for 90 days. Descriptive analyses were done by intention to treat. The primary outcome was @entity64 (ischaemic and @entity548 ) within 90 days. Safety outcomes included @entity548 related to @entity1397 and @entity5442 related to @entity3413 . This study is registered as an International Standard Randomised Controlled Trial (number 35624812) and with ClinicalTrials.gov (NCT00109382). FINDINGS: The median time to @entity64 outcome was 1 day (range 0-62 days). The trial was stopped early due to a failure to recruit @entity1 at the prespecified minimum enrolment rate because of increased use of statins. 14 (7.1%) @entity1 on @entity1397 had a @entity64 within 90 days compared with 21 (10.8%) @entity1 on placebo (risk ratio 0.7 [95% CI 0.3-1.2]; absolute risk reduction -3.8% [95% CI -9.4 to 1.9]; p=0.19). 21 (10.6%) @entity1 on @entity3413 had a @entity64 within 90 days compared with 14 (7.3%) @entity1 on placebo (risk ratio 1.3 [0.7-2.4]; absolute risk increase 3.3% [-2.3 to 8.9]; p=0.25). The interaction between @entity1397 and @entity3413 was not significant (p=0.64). Two @entity1 on @entity1397 had @entity932 compared with none on placebo (absolute risk increase 1.0% [-0.4 to 2.4]; p=0.5). There was no difference between groups for the @entity3413 safety outcomes. INTERPRETATION: Immediately after @entity4905 or @entity64 , @entity1 are at high risk of @entity64 , which might be reduced by using @entity1397 in addition to @entity117 . The @entity548 risks of the combination of @entity117 and @entity1397 do not seem to offset this potential benefit. We were unable to provide evidence of benefit of @entity3413 in this setting. This aggressive prevention approach merits further study.

Fast assessment of @entity64 and XXXX to prevent early recurrence (FASTER): a randomised controlled pilot trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'total stroke', 'minor stroke'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial haemorrhage'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage', 'haemorrhagic'] @entity5442 :: ('MESH:D009220', 'Disease') :: ['myositis'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity4905 :: ('MESH:D002546', 'Disease') :: ['transient ischaemic attack', 'TIA']
@entity4905 :: (MESH:D002546,Disease) :: ['transient ischaemic attack']
